Langley, Richard, Diamant Thaci, Andrew Blauvelt, Tsen-Fang Tsai, Megan Miller, Jenny Yu, Yaung-Kaung Shen, Yin You, Ya-Wen Yang, Kim Papp, Luis Puig, and Peter Foley. “Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated With Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&Amp;2 Phase 3 Trials”. SKIN The Journal of Cutaneous Medicine 6, no. 2 (March 4, 2022): s1. Accessed August 11, 2022. https://jofskin.org/index.php/skin/article/view/1516.